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by Elizabeth Cooper 
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Director: Dr. Stacey Altman 
DERPARTMENT OF KINESIOLOGY 
OBJECTIVE:  To determine if aromatase protein content differs in abdominal and gluteal 
adipose tissue and to determine if there are racial differences in aromatase protein content that 
might influence racial differences in regional body fat distribution in overweight to obese 
premenopausal women. 
MATERIALS/METHODS: Biopsies of the subcutaneous abdominal and gluteal adipose tissue 
were performed in 15 premenopausal women (7 C/8 AA, 25.1 + 1.8 years, BMI 29.5 + 
0.5kg/m(2)). Adipose tissue protein content was measure by western blot analysis. Independent 
sample t-tests were used to determine racial differences in subject characteristics and sex 
hormones. Two-way repeated measure ANOVA (race x region) was used to determine racial 
differences (C versus AA) in estrogen receptor expression in the abdominal and gluteal SAT. 
RESULTS:  Aromatase protein content was not different between races or regions: C abdominal 
0.25±0.06, C gluteal 0.25±0.12, AA abdominal 0.35±0.08, AA gluteal 0.32±0.09 arbitrary units 
(2-way ANOVA; race x region p=0.73, race p=0.46, region p=0.71). 
 
 
CONCLUSIONS: This study showed no significant differences in aromatase protein content 
between regions or races in the observed group. No regional or racial differences in aromatase 
protein content were detected in this study. 
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CHAPTER 1 
INTRODUCTION 
Obesity is one of the leading health issues in the world today, and incidence in the United 
States has risen dramatically over the past decades. 1, 2 Today, about one third of adult Americans 
are obese (33.8%), and no single state has a prevalence of obesity of less than 20%.  Obesity 
carries with it the increased risk of many diseases, including coronary heart disease, Type 2 
diabetes, many cancers, dyslipidemia and stroke.1 
 The distribution of subcutaneous adipose tissue (SAT), fat deposits beneath the skin, may 
have an effect on the severity of disease associated with obesity.  Lower body adipose 
distribution, or gynoid distribution, is associated with a lower risk of metabolic disease than 
upper body distribution, or android distribution.  Gynoid distribution could even have a 
protective effect against disease, as opposed to simply being less harmful as compared to android 
distribution.4, 5  Gynoid obesity is generally of highest prevalence in women, whereas android 
obesity is generally of highest prevalence in men.  However, women’s transition through 
menopause, during which women experience a decrease in estrogen, is characterized by a shift in 
fat mass from gynoid to android distribution.4,5  In order to advance efforts to prevent obesity 
and obesity-related chronic disease, it is important to understand the physiological mechanisms 
behind adipose tissue accumulation and reduction in each region of the body.  
There is great interest in the regulation of SAT since excess adiposity is associated with a 
higher risk of metabolic abnormalities, such as diabetes and atherosclerosis.6  Research suggests 
that estrogen has a significant influence on the distribution of SAT.7–9  Specifically, as 
circulating estrogen levels decrease, especially during menopause, there is an increase in android 
distribution and higher chronic disease risk.5,10,11  Estrogen has been shown to directly influence 
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the metabolism and the location of adipose tissue by altering lipogenesis and lipolysis.12  
Lipogenesis is the synthesis of fatty acids and triglycerides and lipolysis is the reverse, or the 
breakdown of fatty acids and triglycerides. In lipolysis, adipose triglyceride lipase (ATGL) 
initiates the hydrolysis of triacylglycerol (TAG) into diacylglycerols (DG) and free fatty acids 
(FFA). Hormone sensitive lipase (HSL) hydrolyses triacylglycerols, diacylglycerols and 
monoacylglycerols. Monoglyceride lipase hydrolyses monacylglycerol to form glycerol and fatty 
acids. 13 
 Estrogen influences the metabolism and regional distribution of SAT via lipogenesis and 
lipolysis.14–17,13  Aromatase is one of the enzymes that has a great influence on the regulation of 
these estrogens (Figure 1).18,19,20,21   
 
Schematic of Tissue Steroid Metabolism2 
 
Figure 1. Aromatase is an enzyme that converts testosterone and 
androstenedione into estradiol and aromatase, respectively.  
HSD= hydroxysteroid dehydrogenase; ER = Estrogen receptor  
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Aromatase is a key enzyme that regulates steroid levels locally in adipose tissue by 
converting androstenedione into estrone (E1) and testosterone into estradiol (E2).2  Aromatase 
deficiency in humans results in a predominance of androgens over estrogens and abdominal 
obesity, or an android distribution.21  It has also been shown that aromatase mRNA expression 
differs between depots, with higher expression in the gluteal than the abdominal regions in both 
pre- and postmenopausal women.22,23 Therefore, it is logical to assume that the conversion of 
androgens into estrogens (aromatase content) could indicate local concentrations of E2. This 
could have an influence on SAT and distribution via local estrogen exposure.24  For this reason, 
the primary focus of this study was to determine if aromatase protein content differs in 
abdominal and gluteal SAT. 
African Americans (AA) have the highest rates of obesity (44.1%) compared to 
Caucasians (C) who have a prevalence of 32.6%.25  AA tend to gain weight at an earlier age than 
their C counterparts, and maintain a higher weight at comparable ages.26  AAs also tend to have 
different body fat distributions, specifically less visceral adipose tissue for similar age and 
BMI27–29, and even greater amounts of SAT when adjusted for total body fat.27,30,31  It is 
important to understand the mechanisms behind these differences in order to develop and 
research individual treatment methods for obesity and obesity-related diseases. Therefore, a 
second focus of this study was to determine if there are racial differences in aromatase protein 
content that might influence racial differences in regional body fat distribution in 
overweight/obese premenopausal women.
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Statement of the Problem 
Is there a difference in aromatase protein content between gluteal and abdominal adipose 
tissue in premenopausal overweight and obese African American and Caucasian women? 
Research Hypothesis 
Aromatase protein content will be higher in the gluteal region than the abdominal region 
in premenopausal overweight and obese women. 
 Aromatase protein content will be higher in abdominal and gluteal subcutaneous adipose 
tissue of African American than Caucasian premenopausal overweight and obese women. 
 
Delimitations 
 Sixteen healthy premenopausal women, 18-45 years old, overweight or obese [BMI 28-
33 kg/m2], not currently taking hormonal contraceptives or any other form of hormone 
replacement were studied.  Women who had irregular menstrual cycles, a history of hormone 
sensitive cancer, diabetes or insulin resistance, cardiovascular disease including hypertension, 
thyroid dysfunction, abnormal liver or renal function, or woman taking any medications know to 
affect lipid metabolism were excluded from this study.  All women were sedentary, exercised no 
more than 20 minutes twice a week, were weight stable (< 2.0 kg weight change in the past 6 
months), were non-smokers and did not regularly consume alcohol. 
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List of Acronyms 
AA: African American 
C: Caucasian 
SAT: Subcutaneous Adipose Tissue 
FFA: Free fatty acids 
TAG: Triacylglycerols 
ATGL: Adipose Triglyceride Lipase  
HSL: Hormone Sensitive Lipase 
E1: Estrone 
E2: Estradiol 
 
 
 
 
CHAPTER II 
REVIEW OF LITERATURE 
 It is well known that obesity, characterized by excess white adipose tissue, is associated 
with elevated risk of a wide array of morbidities including, but not limited to, heart disease, 
diabetes and certain types of cancer.  It is also known that the type of obesity, or the localization 
of the fat mass, influences the risk associated with developing said morbidities.  Gynoid obesity, 
or obesity with fat mass centered in the hips and thighs, is generally associated with women, 
whereas android obesity, or obesity centered in the abdomen, is generally associated with men.  
However, women’s transition through menopause, during which women experience a decrease in 
estrogen, is characterized by a shift in fat mass from gynoid to android distribution.4,5   Estrogen 
treatment has been shown to prevent the shift from gynoid to android obesity in post-menopausal 
women.16,32  These results suggest that sex steroids may play a significant role in obesity 
patterns. 
 
Regional Differences in Lipolysis 
 Lipolysis is the process of converting TAG from adipocytes into FFA and glycerol13 
using the ATGL33 and HSL enzymes to hydrolyze intracellular triglycerides.34  Lipolysis, 
therefore, is an important process in the reduction of fat mass in any region.  By measuring FFA 
or glycerol in vivo it is possible to estimate local lipolytic activity.  Published data demonstrate 
that there are differences in the lipolytic activity of adipocytes by body region.  By measuring 
FFA in vivo researchers were able to show that lower body adipose tissue lipolytic rates were 
lower than that of the upper body in non-obese and obese premenopausal women.35 Interestingly, 
this study also showed that FFA levels were lower in the lower body of obese women despite 
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higher upper body obesity, which may suggest a mechanism for premenopausal women to 
maintain their gynoid distribution.  In contrast, in a study by Hickner, Fisher and Kohrt (1997), 
glycerol concentrations, an indication of lipolytic rates, were reported to be higher in femoral 
adipose tissue of nonobese premenopausal women as compared to abdominal adipose tissue 
measured via microdialysis recoveries.36  Because of conflicting evidence, it is of great 
importance to pursue further research into the different mechanisms that regulate regional 
lipolysis.  
 
Racial Differences in Lipolysis 
 African American (AA) women become obese at an earlier age than Caucasian (C) 
women and maintain a higher weight at comparable ages across the lifespan.26  Albu et al., 
(1999) showed that AA women have lower basal rates of lipolysis than C women, but did not 
investigate the mechanisms behind this difference.37  Barakat et al., (2002), also found that basal 
lipolytic rates in AA women were lower than those in C women as indicated by fasting FFA and 
glycerol concentrations.38  Researchers did find lower hormone sensitive lipase (HSL) mass in 
AA women despite equal HSL mRNA, suggesting the HSL may be more biologically active in 
AA than C women.   
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Preliminary Data: 
Resting Abdominal Region Lipolysis E2 Infusion 
 
 
 
 
 
 
 
 
 
 
Figure 2. Regional and racial differences between premenopausal overweight to obese C (n=5; age 31.2 ± 
10.03 years; BMI 29.62 ± 2.22 kg/m2) and AA (n=5; age 29.00 ± 8.67 years; BMI 29.39 ± 2.20 kg/m2) women 
show that when estradiol is infused into abdominal SAT in vivo at rest, there is a significant difference  
(p= 0.005*) in percent change of lipolytic response: an increase in lipolysis for C and a decrease for AA. 
 
 
Resting Gluteal Region Lipolyis E2 Infusion 
 
 
 
 
 
Figure 3. When estradiol is infused into gluteal SAT at rest, the difference between AA and C  
response is trending toward significance (p=0.058); a greater decrease in AA than in C. 
 
 
Unpublished pilot data on regional and racial differences between premenopausal 
overweight to obese C (n=5; age 31.2 ± 10.03 years; BMI 29.62 ± 2.22 kg/m2) and AA (n=5; age 
29.00 ± 8.67 years; BMI 29.39 ± 2.20 kg/m2) women show that when estradiol is infused into 
abdominal SAT in vivo at rest, there is a significant difference (p= 0.005) in percent change of 
lipolytic response: an increase in lipolysis for C and a decrease for AA (Figure 2).  When 
* 
* 
* 
* 
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estradiol is infused into gluteal SAT at rest, the difference between AA and C response is 
trending toward significance (p=0.058); a greater decrease in AA than in C (Figure 3).  The 
mechanism(s) behind this difference are not clear. 
 
Estrogens and Lipolysis 
White adipose tissue is an endocrine organ because of it’s ability to store, metabolize and 
export sex hormones and other metabolic hormones affecting metabolism and energy balance 
(e.g. leptin which increases skeletal muscle fatty acid oxidation)39.  Pre-menopausal women 
produce estrogens primarily from the ovaries and several extragonadal sites including 
mesenchymal cells of the adipose tissue, osteoblasts in bone, and vascular endothelial cells.  
Post-menopausal women primarily derive their estrogen from mesenchymal cells of adipose 
tissue.17,23  Since estrogen produced from extragonadal sites is primarily active at the local tissue 
level, the tissue concentrations in these areas may be very high and can be of great significance 
locally.23   
It has been well established that there is an association between the loss of circulating 
estrogen and a shift in body fat distribution in postmenopausal women and premenopausal 
women undergoing sex hormone suppression.4,40,41  Evidence, such as estrogen therapy to treat 
low levels of circulating estrogen, suggests that sex steroids aid in regulating adipose distribution 
as indicated by reversing the shift from android back to gynoid distribution.42,43,44  A study by 
Yükse (2007) showed that hormone replacement therapy (HRT) in postmenopausal women 
supplementing E2 resulted in a significant decrease in both waist circumference and SAT42 
indicating the positive influence of circulating estrogens on the favorable gynoid distribution.  
Davis et al. (2000) showed that HRT with E2 in postmenopausal women resulted in reduced hip 
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and abdominal circumferences as well as fat mass to fat-free mass ratio over the abdomen.44 
These studies support earlier evidence that varying levels of E2 in adipose tissue have been 
shown to play a role in patterns of body fat distribution.  
 
Aromatase 
Aromatase is an enzyme that catalyzes the rate-limiting irreversible aromatization of 
androgens to estrogens.45  After menopause, when women are more inclined to an android 
distribution, there is an increase in SAT aromatase mRNA expression despite lower circulating 
estrogen levels, indicating that postmenopausal women might have increased estrogen in these 
tissues than premenopausal women.46  In premenopausal and postmenopausal women, regional 
mRNA levels were found to be different between adipose tissue depots.  Aromatase mRNA 
expression was higher in the thigh, buttock and flank regions as compared to the abdominal 
region in both pre- and postmenopausal women and was also found to increase with age.22,23  
Similarly, Misso et al. 2005 observed that aromatase mRNA expression was higher in the gluteal 
region than in the abdominal region and that aromatase mRNA expression was significantly 
higher in postmenopasal women.47   This increase in aromatase mRNA expression as women age 
appears to be a mechanism to increase estrogen production in extragonadal sites as circulating 
levels of estrogens decrease. Therefore, adipose depot differences in aromatase mRNA 
expression and aromatase protein content, which are responsible for the conversion of 
testosterone to E2, may be influential in regulating adipose distribution and assist in providing 
potential mechanisms to account for the shift toward a more android distribution observed in the 
studies noted above. 
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Estrogen subtypes 
 Estradiol (E2) is the most biologically active estrogen in mammals48 and is produced 
from the aromatization of testosterone.  E2 has been shown to decrease adiposity, alter the 
release and production of fat hormones, and regulate the growth and localization of adipocytes.  
However, the mechanisms behind this process are still poorly understood.9  Estrone (E1) is 
produced from the aromatization of circulating androstenedione49 and appears to be the primary 
estrogen formed in postmenopausal women.50 
 
Summary 
 The purpose of this study is to investigate differences in aromatase protein content 
between abdominal and gluteal SAT and between AA and C premenopausal overweight and 
obese women. Obesity is a growing health concern in the United States.  With the knowledge 
that estrogens play a role in the distribution of SAT and regulation of lipolysis, and have 
different effects according to region and race, it is significant to find the mechanisms behind this 
process so that effective interventions, such as estrogen therapies after menopause, can be 
developed.  Differences in regional and racial lipolytic responses provide rationale to find the 
mechanisms behind this process in order that researchers and medical professionals can develop 
more effective and appropriate individual strategies based on each person’s unique biology.  
Because estrogens are known to be regulated through specific enzymes, namely aromatase, and 
because little is known about their protein expression between region and particularly between 
races, it is important to develop a more complete understanding in this area. 
 
 
METHODS 
Participants in this study included healthy premenopausal overweight to obese Caucasian 
(C) and African American (AA) women (N=15; C=7; AA=8; BMI=29.5 + 0.5 kg/m2) who were 
sedentary (exercising no more than 20 min/day twice a week) and weight stable (< 2.0 kg weight 
change in past 6 months).  Participants were excluded from this study if they are taking hormonal 
contraceptives, had a history of hormone sensitive cancer, diabetes or insulin resistance, 
cardiovascular disease including hypertension, thyroid dysfunction, abnormal liver or renal 
function, took any medications known to affect lipid metabolism, smoke or regularly consume 
alcohol. 
All participants underwent preliminary testing to ensure all enrollment criteria were met.  
Screening tests included: medical history, pregnancy test, DXA for body composition analysis, 
waist and hip circumferences and completion of menstrual cycle tracking calendar. 
Following acceptance into the study all women were scheduled for two adipose tissue 
biopsies that took place during the early follicular phase of the menstrual cycle, during which 
circulating estrogen and progesterone levels are at their lowest51.  A fasting blood sample was 
collected from an antecubital vein of each participant and analyzed for serum concentrations of 
glycerol, free fatty acids and circulating sex hormones (estradiol, estrone, progesterone, 
testosterone) to confirm menstrual cycle phase.  This study was approved by the Medical Center 
Institutional Review Board at East Carolina University. (UMCIRB #11-077) (Appendix A) 
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Body Composition 
Participants were weighed on an electronic scale with weight recorded to the nearest 0.1 
kg. Height was measured with a standard stadiometer to the nearest centimeter (cm). Waist-to-
hip ratio (WHR) was calculated from measures of minimal waist and hip circumferences 
performed according to previously published guidelines.52  Total percent body fat, fat-free mass 
(lean mass + bone mineral content), and total and regional (android and gynoid) fat mass were 
determined using dual-energy x-ray absorptiometry (DXA; GE Lunar Prodigy Advance, 
Madison, WI).  
 
Adipose Tissue Biopsy 
Participants arrived at the East Carolina Diabetes and Obesity Institute at the East 
Carolina Heart Institute between 0700-0800 h after an overnight fast (≥10 hr) during the 
follicular phase of the menstrual cycle (day 2-8 after the start of menses). On average the biopsy 
visit occurred on day 5 ± 2 of the cycle. Approximately 1 gram of subcutaneous adipose tissue 
was removed under sterile conditions using the needle aspiration technique (14 gauge needle and 
30cc syringe) after administration of local anesthesia (5cc of 1% lidocaine) and 5cc normal 
saline. Biopsies were taken from the abdominal (AB) subcutaneous adipose tissue, 
approximately 5cm lateral to the umbilicus, and the upper gluteal (GL) subcutaneous adipose 
tissue, approximately 5-10 cm from the medial line in the upper quadrant of the buttock. Fat 
tissue was immediately rinsed with Krebs Ringer Bicarbonate buffer containing 1% bovine 
serum albumin. Clots and blood vessels were then removed; tissue was immediately frozen in 
liquid nitrogen and stored at -80 °C for later analysis. 
 
14 
 
Western Blot 
Adipose tissue samples were homogenized glass on glass in a 2:1 (volume-to-weight) 
ratio of cold homogenization buffer (50 mmol/L HEPES [pH 7.4], 1% sodium dodecyl sulfate, 
2% Triton X-100, 2 mmol/L Ethylenediaminetetraacetic acid, 1 mmol/L sodium orthovanadate, 
50 mmol/L sodium fluoride, 1 mmol/L benzamidine, 2 mmol/L dithiothreitol and protease 
inhibitor cocktail [Sigma P8340]). Homogenized samples were rotated for 60 min and 
centrifuged for 30 min at 10,000 x g, both at 4 °C. The supernatant was then removed and protein 
concentration determined by the Pierce BCA protein assay (Thermo Scientific, Rockford, IL). 
Samples were prepared in laemmli sample buffer (Bio-Rad, Hercules, CA) with 5% β- 
mercaptoethanol and heated in a water bath at 90 °C for 5 min. 
Seventy micrograms of protein was loaded and separated on a 10% SDS-polyacrylamide 
gel (Criterion precast gels; Bio-Rad) and electrotransferred to reduced-fluorescence 
polyvinylidene difluoride membranes (Immobilon-FL; Millipore, Bedford, MA).  Membranes 
were blocked for 1 hour at room temperature with Odyssey blocking buffer (LI-COR 
Biosciences, Lincoln, NE) and then probed overnight at 4 °C for aromatase (1:200; sc-14245; 
Santa Cruz Biotechnology, Santa Cruz, CA), and β-actin (1:1000; 926-42212; LI-COR).  Primary 
antibodies were diluted in Odyssey blocking buffer containing 0.2% tween-20. Blots were then 
washed with phosphate buffered saline containing 1% tween-20 (PBS-T) and incubated for 1 h at 
room temperature in fluorescent secondary detection antibodies (IRDye 800 CW-Donkey anti-
Goat and IRDye 680LT Donkey anti-Mouse; LI-COR) diluted in Odyssey Blocking Buffer 
containing 0.2% tween-20 and 1% SDS.  Fluorescence intensity data were quantified using the 
Odyssey infrared imaging system (LI-COR).  All samples were normalized to β-actin protein as 
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well an internal control sample run on each gel and presented in arbitrary units. Myometrium 
served as negative control.53,54 (Figure 4) 
 
Figure 4. Demonstrates the use of the positive and negative controls to verify the results from study 
samples. The positive control for aromatase content used was rat ovary extract. The negative control was 
myometrium. Samples were paired by participant (AA or C) and region (A or G). This blot shows the positive 
control at the correct weight of 58 kilodaltons and the absence of the negative control at 58 kilodaltons. 
 
Blood Samples  
A fasting blood sample was drawn in the morning one day immediately preceding or after 
the biopsy visit. Serum estradiol, progesterone and testosterone were determined by 
Electrochemiluminescence Immunoassay (UniCel® DxC 600i Synchron® Access® Clinical 
System, Beckman Coulter, Inc., Brea, CA). The University of Colorado Denver Clinical and 
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Translational Research Center (CTRC) Core laboratory conducted the following analyses: 
Estrone by conventional radioimmunoassay (Diagnostic Systems Laboratories, Webster, TX; 
200 intra- and inter-assay CV’s respectively 8.7% and 11.7%), dehydroepiandrosterone sulfate 
(DHEA-S) and sex hormone-binding 201 globulin (SHBG) by Electrochemiluminescence 
Immunoassay (Beckman coulter, DHEA-S 2.3% and 3.4%, SHBG 3.6% and 5.7%). 
 
Statistics 
Independent sample t-tests were used to determine racial differences in subject 
characteristics and sex hormones. Triglyceride, estradiol, estrone, progesterone, and SHBG data 
were log transformed before analysis due to its skewed distribution. Paired t-tests were used to 
determine regional differences in aromatase protein content. Two-way repeated measure 
ANOVA (race x region) was used to determine racial differences (Caucasian versus African 
American) in estrogen receptor expression in the abdominal and gluteal SAT. Significance was 
set at a value of p < 0.05. Data are presented as mean + SEM. 
 
 
RESULTS 
Baseline characteristics of participants in the study are included in Table 1 and 
circulating sex hormone levels within one day of the biopsy in Table 2.  African American 
women had elevated android fat mass compared to Caucasian women; all other participant 
characteristics were similar between the racial subgroups. There were no group differences in 
circulating sex hormones. 
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Values are mean + unless otherwise indicated 
aSkewed variable, re-exponentiated to mean 95% confidence interval 
bN=14 (African American N=7), one African American did not have a blood draw 
HC, hormonal contraceptives; SHBG, Sex Hormone-Binding Globulin; DHEA-S, dehydroepiandosterone sulfate 
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Figure 5. Presents evidence of correct band detection for aromatase at the expected 
level of 58 kDa.  Samples were paired by participant according to race (AA or C) 
and region (A or G). Controls used in this figure are an average of aromatase content across all 
participants. 
 
 
Aromatase Protein Content 
Aromatase protein content was not different between races or regions: C abdominal 
0.25±0.06, C gluteal 0.25±0.12, AA abdominal 0.35±0.08, AA gluteal 0.32±0.09 arbitrary units 
(2-way ANOVA; race x region p=0.73, race p=0.46, region p=0.71).  The aromatase protein data 
are depicted in Figure 6. 
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DISCUSSION 
The aim of this study was to examine the potential for differences in aromatase protein 
content between gluteal and abdominal adipose tissue in premenopausal overweight and obese 
African American and Caucasian women.  It was hypothesized that aromatase protein content 
would be higher in the gluteal region than the abdominal region in premenopausal overweight 
and obese women and that aromatase protein content would be higher in abdominal and gluteal 
subcutaneous adipose tissue of African American than Caucasian premenopausal overweight and 
obese women.  This study showed no significant differences in aromatase protein content 
between regions or races in the observed group.  
 Estrogens, produced by enzymes in adipose tissue such as aromatase, have been shown 
to directly influence lipolysis. Estrogen influences the regulation of subcutaneous adipose tissue 
and could thereby help determine body fat distribution. Unpublished pilot data from our lab 
show significant regional and racial differences in in-vivo lipolysis between overweight-to-obese 
(BMI 29.4 + 2.2) premenopausal women in response to local estradiol perfusion (Figure 1, 2).  
Even though previous studies in premenopausal women show regional differences in aromatase 
mRNA levels22,23, no regional or racial differences in aromatase protein content were detected in 
this study.  
Aromatase protein deficiency has been shown to cause a dominance in androgens over 
estrogens and an android body fat distribution21; however, several studies examining aromatase 
enzyme expression, as measured by mRNA, have observed increased aromatase expression as 
women age along with a shift towards android body fat distribution. The same studies also show 
that aromatase enzyme expression was higher in the gluteal regions than abdominal regions in 
both pre- and postmenopausal women despite the shift in body fat distribution.  
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However, Kendrick, 2014 showed that agreement between measurements of mRNA and 
protein content occur only about 40% of the time.55 Consequently, it is not an exercise in 
redundancy to measure both mRNA and protein comparatively or independently. It is important 
to measure mRNA and protein content in order to fully understand the function of the cell. 56 
While it could be assumed that mRNA would directly translate into protein and therefore the two 
would be correlated, that is often not the case. One explanation for this difference could involve 
the many steps between transcription and translation and how much mRNA actually results in 
protein due to difference in transcription rates, efficiency and degredation.57  We measured only 
protein in the present study, as we believe protein content is the relevant measure for our study. 
A measure of aromatase activity would have been preferred to investigate the best functional 
outcome of both transcription and translation, but we were unable to develop an aromatase 
activity for the current study. However, to our knowledge, this is the first study to report 
aromatase protein content at the fat depot regional level and between AA and C women. 
For this study, participants were asked to complete a menstrual cycle tracking calendar, 
and adipose tissue biopsies were performed during the early follicular phase of the menstrual 
cycle. This phase was selected because progesterone and estrogen levels are known to be at their 
lowest and most stable. Since progesterone has been shown to increases aromatase expression 
and estrogen levels53,58 studying the participants during the time of the menstrual cycle with 
lowest estrogen and progesterone likely provided low variance in the hormonal milieu across 
participants. This process could have been further improved by verifying consistency in the 
menstrual cycle across several months, with no missed or late periods and little variation in time 
between menstrual periods. However, there were no variations in circulating sex hormones in 
this group (Table 2), which is ideal for this study in order that these hormones not influence 
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aromatase activity or content. 
One limitation of this study was the small sample size. Recruitment could have been 
limited due to the discomfort of the procedures which included the adipose tissue biopsy that 
could lead to bruising. Previous studies have also further limited African American participants 
with the requirement that both their parents and grandparents be of African American descent. 
No distinction was made in this case and variation in racial descent could have confounded 
results.  
In this study, African American women had significantly higher android mass (kg) (3.4 + 
0.2) than Caucasian women (2.7 + 0.2) (p<0.05) yet no differences in aromatase protein content 
were observed.  While aromatase protein concentration was not different, total protein content 
could be higher due to higher overall fat mass. It appears, in the group studied, that aromatase 
protein content is not a major contributor of body fat distribution. It is possible that aromatase 
activity, as well as other estrogen producing enzymes such as 17BHSD, may be different 
between depots or races, thereby influencing subcutaneous adipose tissue estrogen exposure.  
Men were not considered in this study for several reasons. First, most previous studies 
did not use men in their methodology. Men tend to have more of an android distribution as 
opposed to a gynoid distribution and do not experience a change in said distribution as they age. 
We were also limited to the size of sample in this study. It would be of interest to explore the 
differences in aromatase content between regions and across age in future studies. 
A final limitation of this study may be that there were not lean participants to compare 
our overweight/obese participants to. This would have been a beneficial comparison to determine 
if the concentration of aromatase and rate of lipolysis is different between lean and obese 
participants. A possible difficulty would have been finding lean participants who maintain a 
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similar body fat distribution to the overweight and obese participants. 
In conclusion, we report no significant differences between region or race, contrary to the 
hypothesis. It would benefit future researchers to consider a long-term observation of 
participants to see how aromatase content changes throughout a lifespan and changes in body 
weight and distribution thereof. The addition of a lean group and a male group would add further 
depth the knowledge base on the subject as well. Further research into this area and its influence 
on body composition changes with age and racial discrepancies in disease and body composition 
could lead to evolved treatments of hormone-sensitive disease as well as individualized 
approaches based on age and race. 
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